Emera Inc
EMA
BCE Inc
BCE
TELUS Corp
T
Choice Properties Real Estate Investment Trust
CHP.UN
Power Corporation of Canada
POW
CA Stock MarketDetailed Quotes
MDP Medexus Pharmaceuticals Inc
- 3.090
- -0.050-1.59%
15min DelayMarket Closed Feb 14 16:00 ET
99.68MMarket Cap14.31P/E (TTM)
3.150High3.050Low61.29KVolume3.130Open3.140Pre Close189.59KTurnover5.56052wk High0.21%Turnover Ratio32.26MShares1.47052wk Low0.216EPS TTM92.28MFloat Cap11.250Historical HighLossP/E (Static)29.87MShs Float0.880Historical Low-0.014EPS LYR3.19%Amplitude--Dividend TTM2.12P/B1Lot Size--Div YieldTTM
Medexus Pharmaceuticals Inc Key Stats
Quarterly+Annual
YOY
| (Q3)Dec 31, 2024 | (Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 18.96%29.99M | -13.27%26.3M | -13.54%27.28M | 4.59%113.05M | -9.33%25.96M | -12.25%25.21M | 9.54%30.33M | 36.92%31.56M | 40.93%108.1M | 41.31%28.63M |
| Operating revenue | 18.96%29.99M | -13.27%26.3M | -13.54%27.28M | 4.59%113.05M | -9.33%25.96M | -12.25%25.21M | 9.54%30.33M | 36.92%31.56M | 40.93%108.1M | 41.31%28.63M |
| Cost of revenue | 18.24%14.8M | -13.32%12.18M | -13.05%12.45M | 11.41%53.54M | -7.04%12.66M | -2.19%12.52M | 21.71%14.05M | 41.72%14.32M | 23.94%48.06M | 34.16%13.62M |
| Gross profit | 19.68%15.19M | -13.22%14.13M | -13.94%14.84M | -0.87%59.51M | -11.40%13.31M | -20.34%12.69M | 0.83%16.28M | 33.17%17.24M | 58.30%60.04M | 48.48%15.02M |
| Operating expense | 2.56%11.41M | -21.20%10.03M | -15.27%10.51M | -9.35%46.73M | -14.03%10.48M | -12.13%11.13M | -7.90%12.72M | -3.76%12.4M | 2.48%51.55M | 12.71%12.19M |
| Selling and administrative expenses | 2.62%9.36M | -22.64%7.96M | -16.24%8.7M | -8.84%38.44M | -12.27%8.64M | -11.95%9.12M | -8.67%10.29M | -2.85%10.39M | 9.24%42.16M | 20.84%9.85M |
| -Selling and marketing expense | 0.15%2.61M | -44.64%1.61M | -28.94%2.09M | -7.13%10.58M | -19.97%2.12M | 1.52%2.61M | -3.74%2.91M | -6.62%2.93M | 19.78%11.39M | 50.28%2.65M |
| -General and administrative expense | 3.61%6.74M | -13.95%6.35M | -11.24%6.62M | -9.47%27.86M | -9.43%6.52M | -16.40%6.51M | -10.48%7.37M | -1.28%7.46M | 5.80%30.77M | 12.70%7.2M |
| Research and development costs | 2.41%2M | -14.96%2.01M | -10.62%1.74M | -10.99%8.04M | -21.73%1.78M | -12.17%1.95M | -3.63%2.37M | -6.75%1.95M | -20.13%9.03M | -11.78%2.27M |
| Depreciation amortization depletion | -1.64%60K | -20.83%57K | 1.72%59K | -28.90%251K | -11.76%60K | -32.22%61K | -26.53%72K | -40.21%58K | -11.31%353K | -23.60%68K |
| -Depreciation and amortization | -1.64%60K | -20.83%57K | 1.72%59K | -28.90%251K | -11.76%60K | -32.22%61K | -26.53%72K | -40.21%58K | -11.31%353K | -23.60%68K |
| Operating profit | 141.14%3.78M | 15.36%4.1M | -10.54%4.33M | 50.63%12.79M | -0.07%2.83M | -52.08%1.57M | 52.60%3.55M | 7,834.43%4.84M | 168.59%8.49M | 503.28%2.83M |
| Net non-operating interest income (expenses) | 24.85%-2M | 48.85%-2.16M | 52.27%-2.03M | 1.78%-13.36M | 38.43%-2.22M | 25.23%-2.66M | -28.42%-4.23M | -35.12%-4.26M | -11.31%-13.61M | -16.25%-3.61M |
| Non-operating interest expense | -24.85%2M | -48.85%2.16M | -52.27%2.03M | -1.78%13.36M | -38.43%2.22M | -25.23%2.66M | 28.42%4.23M | 35.12%4.26M | 11.31%13.61M | 16.25%3.61M |
| Other net income (expenses) | -408.87%-905K | -744.97%-2.52M | -233.44%-399K | 798.68%683K | -51.19%389K | 143.09%293K | 81.10%-298K | -80.53%299K | -99.63%76K | 300.50%797K |
| Gain on sale of security | -408.87%-905K | 81.54%-55K | -114.38%-43K | -109.83%-83K | -148.15%-377K | 195.13%293K | 75.06%-298K | -80.88%299K | -95.97%844K | 272.47%783K |
| Special income (charges) | --0 | ---2.46M | ---356K | 199.74%766K | 5,371.43%766K | --0 | --0 | --0 | -368.29%-768K | -97.86%14K |
| -Less:Restructuring and mergern&acquisition | --0 | --0 | --356K | -315.36%-1.65M | -11,714.29%-1.65M | --0 | --0 | --0 | 148.42%768K | 99.42%-14K |
| -Less:Impairment of capital assets | --0 | --2.46M | ---- | --888K | --888K | --0 | --0 | ---- | --0 | ---- |
| Income before tax | 210.69%880K | 40.29%-581K | 114.93%1.9M | 102.10%106K | 8,150.00%990K | 17.19%-795K | 61.71%-973K | 156.96%884K | -31.96%-5.04M | 100.33%12K |
| Income tax | 156.32%147K | -675.83%-691K | -124.46%-57K | 105.11%320K | 103.33%228K | -147.71%-261K | -36.51%120K | 251.30%233K | -565.46%-6.26M | -507.87%-6.84M |
| Earnings from equity interest net of tax | ||||||||||
| Net income | 237.27%733K | 110.06%110K | 200.61%1.96M | -117.53%-214K | -88.89%762K | 64.57%-534K | 59.96%-1.09M | 146.57%651K | 142.41%1.22M | 229.68%6.86M |
| Net income continuous operations | 237.27%733K | 110.06%110K | 200.61%1.96M | -117.53%-214K | -88.89%762K | 64.57%-534K | 59.96%-1.09M | 146.57%651K | 142.41%1.22M | 229.68%6.86M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 237.27%733K | 110.06%110K | 200.61%1.96M | -117.53%-214K | -88.89%762K | 64.57%-534K | 59.96%-1.09M | 146.57%651K | 142.41%1.22M | 229.68%6.86M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 237.27%733K | 110.06%110K | 200.61%1.96M | -117.53%-214K | -88.89%762K | 64.57%-534K | 59.96%-1.09M | 146.57%651K | 142.41%1.22M | 229.68%6.86M |
| Diluted earnings per share | 250.00%0.03 | 108.96%0.0045 | 166.67%0.08 | -116.67%-0.01 | -88.24%0.04 | 71.43%-0.02 | 64.29%-0.05 | 142.86%0.03 | 140.00%0.06 | 225.93%0.34 |
| Basic earnings per share | 250.00%0.03 | 108.96%0.0045 | 166.67%0.08 | -116.67%-0.01 | -88.24%0.04 | 71.43%-0.02 | 64.29%-0.05 | 142.86%0.03 | 140.00%0.06 | 225.93%0.34 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Trending Stocks
Dividend Kings of Canada Dividend Kings of Canada
Dividend Kings In Canada are companies that have increased their Dividend per share for the most consecutive years, reflecting a strong business model and robust financials, and are likely to outperform the market with less volatility. Dividend Kings In Canada are companies that have increased their Dividend per share for the most consecutive years, reflecting a strong business model and robust financials, and are likely to outperform the market with less volatility.